Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Cre-inducible Adeno Associated Virus-mediated Expression of P301L Mutant Tau Causes Motor Deficits and Neuronal Degeneration in the Substantia Nigra.

You Y, Botros MB, Enoo AAV, Bockmiller A, Herron S, Delpech JC, Ikezu T.

Neuroscience. 2019 Dec 1;422:65-74. doi: 10.1016/j.neuroscience.2019.10.001. Epub 2019 Nov 2.

PMID:
31689387
2.

Proteomic Profiling of Extracellular Vesicles Isolated From Cerebrospinal Fluid of Former National Football League Players at Risk for Chronic Traumatic Encephalopathy.

Muraoka S, Jedrychowski MP, Tatebe H, DeLeo AM, Ikezu S, Tokuda T, Gygi SP, Stern RA, Ikezu T.

Front Neurosci. 2019 Oct 9;13:1059. doi: 10.3389/fnins.2019.01059. eCollection 2019.

3.

Emerging roles of extracellular vesicles in neurodegenerative disorders.

You Y, Ikezu T.

Neurobiol Dis. 2019 Oct;130:104512. doi: 10.1016/j.nbd.2019.104512. Epub 2019 Jun 20. Review.

PMID:
31229685
4.

Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux.

Luengo E, Buendia I, Fernández-Mendívil C, Trigo-Alonso P, Negredo P, Michalska P, Hernández-García B, Sánchez-Ramos C, Bernal JA, Ikezu T, León R, López MG.

J Pineal Res. 2019 Aug;67(1):e12578. doi: 10.1111/jpi.12578. Epub 2019 Apr 29.

PMID:
30943316
5.

Neuroimmune Crosstalk through Extracellular Vesicles in Health and Disease.

Delpech JC, Herron S, Botros MB, Ikezu T.

Trends Neurosci. 2019 May;42(5):361-372. doi: 10.1016/j.tins.2019.02.007. Epub 2019 Mar 26. Review.

PMID:
30926143
6.

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borràs FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MÁ, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Górecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekström K, El Andaloussi S, Elie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Försönits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, Gámez-Valero A, Gardiner C, Gärtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Görgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinke DJ 2nd, Kornek M, Kosanović MM, Kovács ÁF, Krämer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lässer C, Laurent LC, Lavieu G, Lázaro-Ibáñez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Linē A, Linnemannstöns K, Llorente A, Lombard CA, Lorenowicz MJ, Lörincz ÁM, Lötvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, Möller A, Møller Jørgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-'t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loghlen A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Østergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Saá P, Sahoo S, Salas-Huenuleo E, Sánchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schøyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL 2nd, Soares RP, Sódar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žėkas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK.

J Extracell Vesicles. 2018 Nov 23;7(1):1535750. doi: 10.1080/20013078.2018.1535750. eCollection 2018.

7.

Transcriptional and Epigenetic Regulation of Microglia in Health and Disease.

Yeh H, Ikezu T.

Trends Mol Med. 2019 Feb;25(2):96-111. doi: 10.1016/j.molmed.2018.11.004. Epub 2018 Dec 18. Review.

PMID:
30578089
8.

TIA1 regulates the generation and response to toxic tau oligomers.

Jiang L, Ash PEA, Maziuk BF, Ballance HI, Boudeau S, Abdullatif AA, Orlando M, Petrucelli L, Ikezu T, Wolozin B.

Acta Neuropathol. 2019 Feb;137(2):259-277. doi: 10.1007/s00401-018-1937-5. Epub 2018 Nov 21.

9.

Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans.

Ikezu T, Chen C, DeLeo AM, Zeldich E, Fallin MD, Kanaan NM, Lunetta KL, Abraham CR, Logue MW, Farrer LA.

J Neuroimmune Pharmacol. 2018 Jun;13(2):254-264. doi: 10.1007/s11481-018-9781-x. Epub 2018 Mar 7.

10.

Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.

Clayton KA, Van Enoo AA, Ikezu T.

Front Neurosci. 2017 Dec 12;11:680. doi: 10.3389/fnins.2017.00680. eCollection 2017. Review.

11.

Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo.

Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Al Abdullatif A, Ferragud A, Botelho E, Ballance HI, Dhawan U, Boudeau S, Cruz AL, Kashy D, Wong A, Goldberg LR, Yazdani N, Zhang C, Ung CY, Tripodis Y, Kanaan NM, Ikezu T, Cottone P, Leszyk J, Li H, Luebke J, Bryant CD, Wolozin B.

Nat Neurosci. 2018 Jan;21(1):72-80. doi: 10.1038/s41593-017-0022-z. Epub 2017 Nov 20.

12.

Extracellular Vesicle Biology in Alzheimer's Disease and Related Tauopathy.

DeLeo AM, Ikezu T.

J Neuroimmune Pharmacol. 2018 Sep;13(3):292-308. doi: 10.1007/s11481-017-9768-z. Epub 2017 Nov 28. Review.

13.

The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.

Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O.

Immunity. 2017 Sep 19;47(3):566-581.e9. doi: 10.1016/j.immuni.2017.08.008.

14.

A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells.

Varnum MM, Clayton KA, Yoshii-Kitahara A, Yonemoto G, Koro L, Ikezu S, Ikezu T.

J Biol Chem. 2017 Jun 23;292(25):10651-10663. doi: 10.1074/jbc.M116.759159. Epub 2017 May 10.

15.

Occurrence of Crohn's disease with Parkinson's disease.

Fujioka S, Curry SE, Kennelly KD, Tacik P, Heckman MG, Tsuboi Y, Strongosky AJ, van Gerpen JA, Uitti RJ, Ross OA, Ikezu T, Wszolek ZK.

Parkinsonism Relat Disord. 2017 Apr;37:116-117. doi: 10.1016/j.parkreldis.2017.01.013. Epub 2017 Feb 10.

PMID:
28215729
16.

Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2017 May;133(5):785-807. doi: 10.1007/s00401-017-1668-z. Epub 2017 Jan 9.

17.

Corrigendum to "Syk and ye shall find" [EBioMedicine 2 (11) (2015) 190-1591].

Wolozin B, Ikezu T.

EBioMedicine. 2016 Jun;8:349. doi: 10.1016/j.ebiom.2016.05.033. Epub 2016 May 29. No abstract available.

18.

Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy.

Stern RA, Tripodis Y, Baugh CM, Fritts NG, Martin BM, Chaisson C, Cantu RC, Joyce JA, Shah S, Ikezu T, Zhang J, Gercel-Taylor C, Taylor DD.

J Alzheimers Dis. 2016;51(4):1099-109. doi: 10.3233/JAD-151028.

19.

Syk and Yea Shall Find.

Wolozin B, Ikezu T.

EBioMedicine. 2015 Nov 10;2(11):1590-1. doi: 10.1016/j.ebiom.2015.11.012. eCollection 2015 Nov. No abstract available.

20.

Impairment of PARK14-dependent Ca(2+) signalling is a novel determinant of Parkinson's disease.

Zhou Q, Yen A, Rymarczyk G, Asai H, Trengrove C, Aziz N, Kirber MT, Mostoslavsky G, Ikezu T, Wolozin B, Bolotina VM.

Nat Commun. 2016 Jan 12;7:10332. doi: 10.1038/ncomms10332.

21.

GluN2D N-Methyl-d-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia.

Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, Monaghan DT.

J Pharmacol Exp Ther. 2016 Mar;356(3):702-11. doi: 10.1124/jpet.115.230391. Epub 2015 Dec 16.

22.

Depletion of microglia and inhibition of exosome synthesis halt tau propagation.

Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kügler S, Ikezu T.

Nat Neurosci. 2015 Nov;18(11):1584-93. doi: 10.1038/nn.4132. Epub 2015 Oct 5.

23.

The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease.

Varnum MM, Kiyota T, Ingraham KL, Ikezu S, Ikezu T.

Neurobiol Aging. 2015 Nov;36(11):2995-3007. doi: 10.1016/j.neurobiolaging.2015.07.027. Epub 2015 Aug 1.

24.

miR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction.

Woodbury ME, Freilich RW, Cheng CJ, Asai H, Ikezu S, Boucher JD, Slack F, Ikezu T.

J Neurosci. 2015 Jul 1;35(26):9764-81. doi: 10.1523/JNEUROSCI.4790-14.2015.

25.

PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation.

Jun G, Asai H, Zeldich E, Drapeau E, Chen C, Chung J, Park JH, Kim S, Haroutunian V, Foroud T, Kuwano R, Haines JL, Pericak-Vance MA, Schellenberg GD, Lunetta KL, Kim JW, Buxbaum JD, Mayeux R, Ikezu T, Abraham CR, Farrer LA.

Ann Neurol. 2014 Sep;76(3):379-92. doi: 10.1002/ana.24219. Epub 2014 Jul 29.

26.

Tau-tubulin kinase.

Ikezu S, Ikezu T.

Front Mol Neurosci. 2014 Apr 28;7:33. doi: 10.3389/fnmol.2014.00033. eCollection 2014. Review.

27.

Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1.

Asai H, Ikezu S, Woodbury ME, Yonemoto GM, Cui L, Ikezu T.

Am J Pathol. 2014 Mar;184(3):808-18. doi: 10.1016/j.ajpath.2013.11.026. Epub 2014 Jan 10.

28.

Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia.

Freilich RW, Woodbury ME, Ikezu T.

PLoS One. 2013 Nov 11;8(11):e79416. doi: 10.1371/journal.pone.0079416. eCollection 2013.

29.

Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration.

Woodbury ME, Ikezu T.

J Neuroimmune Pharmacol. 2014 Mar;9(2):92-101. doi: 10.1007/s11481-013-9501-5. Epub 2013 Sep 21. Review.

30.

Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.

Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, St George-Hyslop P, Ikezu T, Schilling S, Demuth HU, Lemere CA.

Am J Pathol. 2013 Aug;183(2):369-81. doi: 10.1016/j.ajpath.2013.05.005. Epub 2013 Jun 7.

31.

The spectrum of disease in chronic traumatic encephalopathy.

McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC.

Brain. 2013 Jan;136(Pt 1):43-64. doi: 10.1093/brain/aws307. Epub 2012 Dec 2. Erratum in: Brain. 2013 Oct;136(Pt 10):e255.

32.

The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain.

Varnum MM, Ikezu T.

Arch Immunol Ther Exp (Warsz). 2012 Aug;60(4):251-66. doi: 10.1007/s00005-012-0181-2. Epub 2012 Jun 19. Review.

33.

Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies.

Vanderweyde T, Yu H, Varnum M, Liu-Yesucevitz L, Citro A, Ikezu T, Duff K, Wolozin B.

J Neurosci. 2012 Jun 13;32(24):8270-83. doi: 10.1523/JNEUROSCI.1592-12.2012.

34.

Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model.

Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Upreti C, Kracht JM, Ericsson M, Wojnarowicz MW, Goletiani CJ, Maglakelidze GM, Casey N, Moncaster JA, Minaeva O, Moir RD, Nowinski CJ, Stern RA, Cantu RC, Geiling J, Blusztajn JK, Wolozin BL, Ikezu T, Stein TD, Budson AE, Kowall NW, Chargin D, Sharon A, Saman S, Hall GF, Moss WC, Cleveland RO, Tanzi RE, Stanton PK, McKee AC.

Sci Transl Med. 2012 May 16;4(134):134ra60. doi: 10.1126/scitranslmed.3003716.

35.

Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease?

Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ.

J Alzheimers Dis. 2012;29(2):329-40. doi: 10.3233/JAD-2011-111472.

36.

FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders.

Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):E1339-48. doi: 10.1073/pnas.1102349108. Epub 2011 Oct 31. Erratum in: Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21282.

37.

AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice.

Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T.

Gene Ther. 2012 Jul;19(7):724-33. doi: 10.1038/gt.2011.126. Epub 2011 Sep 15.

38.

The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

Lan X, Kiyota T, Hanamsagar R, Huang Y, Andrews S, Peng H, Zheng JC, Swindells S, Carlson GA, Ikezu T.

J Neuroimmune Pharmacol. 2012 Jun;7(2):412-23. doi: 10.1007/s11481-011-9304-5. Epub 2011 Aug 9.

39.

HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes.

Lan X, Xu J, Kiyota T, Peng H, Zheng JC, Ikezu T.

J Immunol. 2011 Jun 15;186(12):6925-32. doi: 10.4049/jimmunol.1100211. Epub 2011 May 6.

40.

Neuroimmune pharmacology as a sub-discipline of medical neuroscience in the medical school curriculum.

Freilich RW, Ikezu T.

J Neuroimmune Pharmacol. 2011 Mar;6(1):41-56. doi: 10.1007/s11481-010-9250-7. Epub 2010 Nov 20. Review.

41.

Phenolic bis-styrylbenzenes as β-amyloid binding ligands and free radical scavengers.

Flaherty DP, Kiyota T, Dong Y, Ikezu T, Vennerstrom JL.

J Med Chem. 2010 Nov 25;53(22):7992-9. doi: 10.1021/jm1006929. Epub 2010 Nov 1.

42.

Distinct neuronal localization of microtubule-associated protein 4 in the mammalian brain.

Tokuraku K, Okuyama S, Matsushima K, Ikezu T, Kotani S.

Neurosci Lett. 2010 Oct 29;484(2):143-7. doi: 10.1016/j.neulet.2010.08.038. Epub 2010 Aug 19.

PMID:
20727942
43.

Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity.

Xu J, Tsutsumi K, Tokuraku K, Estes KA, Hisanaga S, Ikezu T.

J Neurochem. 2011 Jan;116(2):192-204. doi: 10.1111/j.1471-4159.2010.06824.x.

44.

CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice.

Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T.

FASEB J. 2010 Aug;24(8):3093-102. doi: 10.1096/fj.10-155317. Epub 2010 Apr 6.

45.

Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice.

Xu J, Sato S, Okuyama S, Swan RJ, Jacobsen MT, Strunk E, Ikezu T.

FASEB J. 2010 Aug;24(8):2904-15. doi: 10.1096/fj.09-150144. Epub 2010 Mar 30.

PMID:
20354135
46.

Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes.

Tokuraku K, Marquardt M, Ikezu T.

PLoS One. 2009 Dec 30;4(12):e8492. doi: 10.1371/journal.pone.0008492.

47.

CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction.

Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T.

PLoS One. 2009 Jul 10;4(7):e6197. doi: 10.1371/journal.pone.0006197.

48.

The aging of human-immunodeficiency-virus-associated neurocognitive disorders.

Ikezu T.

J Neuroimmune Pharmacol. 2009 Jun;4(2):161-2. doi: 10.1007/s11481-009-9155-5. Epub 2009 May 5. No abstract available.

PMID:
19415503
49.

AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.

Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T.

Mol Ther. 2009 May;17(5):803-9. doi: 10.1038/mt.2009.44. Epub 2009 Mar 10.

50.

Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1.

Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, Swan RJ, Schlautman JD, Ciborowski P, Ikezu T.

J Neurosci. 2008 Dec 31;28(53):14511-21. doi: 10.1523/JNEUROSCI.3417-08.2008.

Supplemental Content

Support Center